Syncona portfolio company Beacon's gene therapy shows positive Phase II/III results
Syncona Limited announced that its portfolio company, Beacon Therapeutics, has delivered positive topline results from its Phase II/III pivotal VISTA study for laru-zova, a gene therapy for X-linked retinitis pigmentosa. The study met its FDA-endorsed primary endpoint, demonstrating statistically significant improvemen